Eli Lilly Files 8-K on Financials

TL;DR

Lilly filed an 8-K on Jan 14, 2025, for financial reporting.

AI Summary

Eli Lilly and Company filed an 8-K on January 14, 2025, to report on its results of operations and financial condition. The filing includes various financial statements and exhibits related to the company's financial performance. Specific details on the financial results or any new developments are not elaborated in the provided text, but the filing indicates a standard reporting event.

Why It Matters

This filing provides an official update on Eli Lilly's financial condition, which is crucial for investors to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any new material adverse information.

Key Players & Entities

• ELI LILLY & Co (company) — Filer
• 0000059478-25-000005 (accession_number) — Filing identifier
• 20250114 (date) — Filing date
• INDIANAPOLIS (location) — Company headquarters
• IN (state) — Company headquarters state

FAQ

Filing Documents

• lly-20250114.htm (8-K) — 50KB
• jpm_2025guidancexpressrele.htm (EX-99.1) — 21KB
• image_0a.jpg (GRAPHIC) — 25KB
• image_1a.jpg (GRAPHIC) — 86KB
• 0000059478-25-000005.txt ( ) — 448KB
• lly-20250114.xsd (EX-101.SCH) — 4KB
• lly-20250114_def.xml (EX-101.DEF) — 19KB
• lly-20250114_lab.xml (EX-101.LAB) — 37KB
• lly-20250114_pre.xml (EX-101.PRE) — 20KB
• lly-20250114_htm.xml (XML) — 10KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 14, 2025, at approximately 5:15 p.m. Eastern time, Eli Lilly and Company (the "Company") will participate in a fireside chat at the 2025 J.P. Morgan Healthcare Conference. During the discussion, Lilly will provide an update on earnings guidance for 2024, will share its 2025 revenue guidance range, and will discuss overall market trends. Lilly issued a press release relating to the update, attached hereto as Exhibit 99.1, and incorporated herein by reference. A live audio webcast of the conference discussion, press release and associated presentation, will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 30 days. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated January 1 4 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Lucas Montarce Name: Lucas Montarce Title: Executive Vice President and Chief Financial Officer Date: January 14, 2025

View Full Filing

View this 8-K filing on SEC EDGAR